【Cited FineTest Antibody】 Current Research on Bladder Cancer‎ and Proteomics

FineTest antibody contributes to the research on bladder cancer‎ and proteomics. The co-immunoprecipitation assay is designed to measure PGK1 in cell lines and tumor tissues.

Publication Details
Article Title: Integrated proteogenomic characterization of urothelial carcinoma of the bladder
Journal Title: Journal of Hematology & Oncology
DOI: 10.1186/s13045-022-01291-7
IF: 17.388
PMID: 35659036

Abstract:     Background: Urothelial carcinoma (UC) is the most common pathological type of bladder cancer, a malignant tumor. However, an integrated multi-omics analysis of the Chinese UC patient cohort is lacking. Methods: We performed an integrated multi-omics analysis, including whole-exome sequencing, RNA-seq, proteomic, and phosphoproteomic analysis of 116 Chinese UC patients, comprising 45 non-muscle-invasive bladder cancer patients (NMIBCs) and 71 muscle-invasive bladder cancer patients (MIBCs). Result: Proteogenomic integration analysis indicated that SND1 and CDK5 amplifications on chromosome 7q were associated with the activation of STAT3, which was relevant to tumor proliferation. Chromosome 5p gain in NMIBC patients was a high-risk factor, through modulating actin cytoskeleton implicating in tumor cells invasion. Phosphoproteomic analysis of tumors and morphologically normal human urothelium produced UC-associated activated kinases, including CDK1 and PRKDC. Proteomic analysis identified three groups, U-I, U-II, and U-III, reflecting distinct clinical prognosis and molecular signatures. Immune subtypes of UC tumors revealed a complex immune landscape and suggested the amplification of TRAF2 related to the increased expression of PD-L1. Additionally, increased GARS, related to subtype U-II, was validated to promote pentose phosphate pathway by inhibiting activities of PGK1 and PKM2. Conclusions: This study provides a valuable resource for researchers and clinicians to further identify molecular pathogenesis and therapeutic opportunities in urothelial carcinoma of the bladder.

Keywords:   Urothelial carcinoma of the bladder, Proteomics, Phosphoproteomics, Genome, RNA-seq, Proteomic subtype, Immune clusters, GARS

Co-immunoprecipitation

Validated Image

Figure Source: J Hematol Oncol. 2022 Jun 3;15(1):76. doi: 10.1186/s13045-022-01291-7.

Fig. 8.   GARS promotes bladder cancer cell proliferation through non-canonical function. A GARS was differentially expressed in tumors and MNUs (p value from Wilcoxon rank-sum test). B The expression levels of indicated proteins and global K-Gly in tumor tissues compared with those of adjacent normal tissues. C The pentose phosphate pathway was activated, while glycolysis was downregulated in GARS-overexpressing cells. D Global K-Gly levels in T24 and 5637 GARS-overexpressing cell lines. E Interaction between GARS and PGK1, and interaction between GARS and PKM2, in both 5637 and T24 cell lines detected by co-immunoprecipitation assays. F Interaction of GARS with PGK1 and PKM2 in the bladder cancer tumor tissues, detected by co-immunoprecipitation assays. G K-Gly levels of PGK1 and PKM2 in both 5637 and T24 GARS-overexpressing cells. H Enzymatic activities of PGK1 and PKM2 in T24 GARS-overexpressing cells. I Beta-alanine inhibits K-Gly formation. J The effect of beta-alanine and GARS on T24 cells xenografts in nude mice. K A model depicting the regulation of GARS.